




Instance: composition-en-3713afe50f1010dc6d3a525f7492a818
InstanceOf: CompositionUvEpi
Title: "Composition for idefirix Package Leaflet"
Description:  "Composition for idefirix Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1c08ca6712ac1c2e1d3907bbfff2bcf1)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - idefirix"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Idefirix is and what it is used for  </li>
<li>What you need to know before you are given Idefirix  </li>
<li>How to use Idefirix </li>
<li>Possible side effects  </li>
<li>How to store Idefirix </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What idefirix is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What idefirix is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Idefirix contains the active substance imlifidase, which belongs to a group of medicines called 
immunosuppressants. It is given before your kidney transplantation to prevent the immune system 
(your body's defences) from rejecting the donated kidney. </p>
<p>Idefirix works by breaking down a type of antibody in the body called immunoglobulin G (IgG), 
which is involved in destroying 'foreign' or harmful substances. </p>
<p>Imlifidase is a protein from a bacterium called Streptococcus pyogenes. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take idefirix"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take idefirix"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You must not be given Idefirix 
- If you are allergic to imlifidase or any of the other ingredients of this medicine (listed in 
section 6). 
- If you have a severe infection. 
- If you have a blood disorder called thrombotic thrombocytopenic purpura (TTP), that results in 
blood clots forming in small blood vessels throughout the body. </p>
<p>Warnings and precautions  </p>
<p>Infusion reactions 
Idefirix contains a protein and it can cause allergic reactions in some people. You will receive 
medicines to reduce the risk of an allergic reaction. If you get any symptoms of an allergic reaction, 
such as severe rash, shortness of breath, feeling hot, flushing, during the infusion ( drip ), the infusion 
may need to be slowed down or stopped. When these symptoms go away, or improve, the infusion can 
be continued. </p>
<p>Infections 
IgG is important for protecting you against infections and since Idefirix breaks down IgG, you will 
receive antibiotics to reduce the risk of infections. </p>
<p>Antibody-mediated rejection (AMR)<br />
Your body will produce new IgG antibodies, which may attack the transplanted kidney. Your doctor 
will monitor you closely and you will receive medicines to reduce the risk of rejection. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents under 18 years of age because it has not been 
studied in this age group. </p>
<p>Other medicines and Idefirix 
Tell your doctor if you are using, have recently used or might use any other medicines. Idefirix can 
affect the way some medicines work, and the dose of these may have to be adjusted.  </p>
<p>As Idefirix breaks down IgG, IgG-based medicines may not work if given at the same time as Idefirix. 
This includes the following medicines:</p>
<ul>
<li>basiliximab (used to prevent rejection of kidney transplants) </li>
<li>rituximab (used to treat cancers such as non-Hodgkin s lymphoma and chronic lymphocytic 
leukaemia and inflammatory diseases such as rheumatoid arthritis) </li>
<li>alemtuzumab (used to treat a form of multiple sclerosis) </li>
<li>adalimumab (used to treat inflammatory diseases such as rheumatoid arthritis, ankylosing 
spondylitis, psoriasis, Crohn s disease and ulcerative colitis) </li>
<li>denosumab (used to treat osteoporosis) </li>
<li>belatacept (used to prevent rejection of kidney transplants) </li>
<li>etanercept (used to treat inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, 
ankylosing spondylitis and psoriasis) </li>
<li>rabbit anti-thymocyte globulin (rATG) (used to prevent rejection of kidney transplants) </li>
<li>intravenous immunoglobulin (IVIg) (used to increase abnormally low immunoglobulin levels in 
the blood or to treat inflammatory diseases such as Guillain-Barr  syndrome, Kawasaki disease 
and chronic inflammatory demyelinating polyneuropathy). </li>
</ul>
<p>Pregnancy and breast-feeding 
Idefirix is not recommended during pregnancy. 
Talk to your doctor if you think you may be pregnant. </p>
<p>It is not known whether Idefirix passes into breast milk. You should not breast-feed if you are being 
treated with Idefirix. </p>
<p>Idefirix contains sodium<br />
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take idefirix"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take idefirix"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Idefirix will be prescribed by a doctor with experience in kidney transplantation and it is for use in a 
hospital. The medicine will be given by infusion into your vein over about 15 minutes.  </p>
<p>A healthcare professional will calculate the right dose for you based on your weight. Idefirix is usually 
given as a single dose, but your doctor may decide to give a second dose before the transplantation.  </p>
<p>Information for healthcare professionals on dose calculation, preparation and infusion of Idefirix is 
given at the end of this leaflet. </p>
<p>If you receive more Idefirix than you should 
During and after the infusion you will be closely monitored. Healthcare professionals will check for 
any side effects. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Tell your doctor immediately if you notice any of the following:</p>
<ul>
<li>Signs of infection, such as fever, chills, cough, feeling weak or generally unwell (very common </li>
<li>may affect more than 1 in 10 people). </li>
<li>Signs of an infusion reaction, such as severe rash, shortness of breath, feeling hot, flushing 
(common - may affect up to 1 in 10 people).  </li>
<li>Muscle pain or fatigue (symptoms of myalgia) (common - may affect up to 1 in 10 people). </li>
</ul>
<p>Other side effects include: </p>
<p>Common (may affect up to 1 in 10 people):</p>
<ul>
<li>Infections: lung infection (pneumonia), infections of the blood (sepsis), abdominal infection, 
upper respiratory tract infection, adenovirus infection, parvovirus infection, urinary tract 
infection, influenza, wound infection, post-operative wound infection, catheter site infection </li>
<li>Transplant rejection (IgG antibodies will try to reject your donor kidney and you can feel 
general discomfort) </li>
<li>High or low blood pressure (symptoms of low blood pressure can be dizziness and symptoms of 
high blood pressure can be headache)  </li>
<li>Low number of red blood cells (anaemia) </li>
<li>Dizziness at change of body position, e.g. when standing up </li>
<li>Headache </li>
<li>Burst blood vessel in the eye </li>
<li>Decreased vision </li>
<li>Increased heart rate </li>
<li>Infusion site pain </li>
<li>Increased liver enzymes (seen in blood tests) </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects, you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store idefirix"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store idefirix"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. Idefirix is stored in the hospital pharmacy. </p>
<p>Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2-8 C). Do not freeze. Store in the original package in order to protect from 
light.  </p>
<p>Chemical and physical in-use stability after reconstitution and dilution has been demonstrated for 
24 hours at 2-8 C and for 4 hours at 25 C during this period. </p>
<p>Do not use this medicine if you notice particulate matter or discolouration after reconstitution. </p>
<p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines 
you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Idefirix contains<br />
- The active substance is imlifidase. Each vial contains 11 mg imlifidase. After reconstitution, 
each mL of concentrate contains 10 mg imlifidase.<br />
- The other ingredients are mannitol, polysorbate 80, trometamol, disodium edetate dihydrate and 
hydrochloric acid (for pH adjustment). See section 2  Idefirix contains sodium . </p>
<p>What Idefirix looks like and contents of the pack 
- Idefirix is supplied as a glass vial containing a powder for concentrate for solution for infusion 
(powder for concentrate). The powder is a white freeze-dried cake. 
- Packs contain 1 or 2 vials. </p>
<p>Marketing Authorisation Holder<br />
Hansa Biopharma AB<br />
P.O. Box 220 07 Lund<br />
Sweden </p>
<p>Manufacturer 
Biotechnologines farmacijos centras Biotechpharma UAB 
Mokslininku street 4 
LT-08412 Vilnius 
Lithuania </p>
<p>Propharma Group The Netherlands B.V. 
Schipholweg 2316 ZL, Leiden 
Netherlands </p>
<p>This leaflet was last revised in  </p>
<p>This medicine has been given  conditional approval . This means that there is more evidence to come 
about this medicine.<br />
The European Medicines Agency will review new information on this medicine at least every year and 
this leaflet will be updated as necessary. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-3713afe50f1010dc6d3a525f7492a818
InstanceOf: CompositionUvEpi
Title: "Composition for idefirix Package Leaflet"
Description:  "Composition for idefirix Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1c08ca6712ac1c2e1d3907bbfff2bcf1)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - idefirix"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at få Idefirix  </li>
<li>Sådan vil du få Idefirix </li>
<li>Bivirkninger  </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What idefirix is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What idefirix is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Idefirix indeholder det aktive stof imlifidase, der tilhører en gruppe af lægemidler kaldet 
immunsuppressive stoffer. Det gives før din nyretransplantation for at hindre immunsystemet (din 
krops forsvar) i at afstøde den donerede nyre. </p>
<p>Idefirix virker ved at nedbryde en type antistof i kroppen ved navn immunglobulin G (IgG), som er 
med til at ødelægge "fremmede" eller skadelige stoffer. </p>
<p>Imlifidase er et protein fra bakterien Streptococcus pyogenes. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take idefirix"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take idefirix"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Idefirix 
- Hvis du er allergisk over for imlifidase eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6). 
- Hvis du har en alvorlig infektion. 
- Hvis du har blodsygdommen trombotisk trombocytopenisk purpura (TTP), som medfører 
dannelse af blodpropper i små blodkar rundt omkring i kroppen. </p>
<p>Advarsler og forsigtighedsregler  </p>
<p>Infusionsreaktioner 
Idefirix indeholder et protein, og det kan forårsage allergiske reaktioner hos nogle personer. Du vil få 
medicin for at mindske risikoen for en allergisk reaktion. Hvis du får symptomer på en allergisk 
reaktion, såsom svært udslæt, åndenød, varmefornemmelse, rødmen, under infusionen ("droppet"), kan 
det være nødvendigt at nedsætte infusionshastigheden eller at standse infusionen. Når disse 
symptomer forsvinder eller bedres, kan infusionen fortsætte. </p>
<p>Infektioner 
IgG er vigtigt for at beskytte dig mod infektioner, og da Idefirix nedbryder IgG, vil du få antibiotika til 
at mindske risikoen for infektioner. </p>
<p>Antistofmedieret afstødning (AMR)<br />
Din krop vil producere nye IgG-antistoffer, som kan angribe den transplanterede nyre. Din læge vil 
overvåge dig nøje, og du vil få medicin til at mindske risikoen for afstødning. </p>
<p>Børn og unge 
Giv ikke dette lægemiddel til børn eller unge under 18 år, da det ikke er undersøgt i denne 
aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med Idefirix 
Fortæl det altid til lægen, hvis du tager andre lægemidler, for nylig har taget andre lægemidler eller 
planlægger at tage andre lægemidler. Idefirix kan påvirke måden, visse andre lægemidler virker på. 
Derfor kan det blive nødvendigt at justere dosis af disse.  </p>
<p>Fordi Idefirix nedbryder IgG, kan det ske, at IgG-baserede lægemidler ikke virker, hvis de gives 
samtidig med Idefirix. Det drejer sig om følgende lægemidler:</p>
<ul>
<li>basiliximab (anvendes til at forhindre afstødning af transplanterede nyrer) </li>
<li>rituximab (anvendes til at behandle kræft såsom non-Hodgkins lymfom og kronisk lymfatisk 
leukæmi og betændelsessygdomme såsom rheumatoid arthritis) </li>
<li>alemtuzumab (anvendes til at behandle en form for multipel sklerose) </li>
<li>adalimumab (anvendes til at behandle betændelsessygdomme såsom reumatoid artrit 
(leddegigt), ankyloserende spondylitis (Bechterews sygdom), psoriasis, Crohns sygdom og 
blødende tyktarmsbetændelse (colitis ulcerosa)) </li>
<li>denosumab (anvendes til at behandle osteoporose) </li>
<li>belatacept (anvendes til at forhindre afstødning af transplanterede nyrer) </li>
<li>etanercept (anvendes til at behandle betændelsessygdomme såsom reumatoid artrit (leddegigt), 
psoriasisartrit, ankyloserende spondylitis (Bechterews sygdom) og psoriasis) </li>
<li>kanin-antithymocytglobulin (rATG) (anvendes til at forhindre afstødning af transplanterede 
nyrer) </li>
<li>intravenøs immunoglobulin (IVIg) (anvendes til at forøge abnormt lave immunglobulinniveauer 
i blodet eller til at behandle betændelsessygdomme såsom Guillain-Barrés syndrom, Kawasakis 
sygdom og kronisk inflammatorisk demyeliniserende polyneuropati). </li>
</ul>
<p>Graviditet og amning 
Idefirix frarådes under graviditet. 
Kontakt lægen, hvis du tror, at du kan være gravid. </p>
<p>Det vides ikke, om Idefirix udskilles i modermælken. Du bør ikke amme, hvis du behandles med 
Idefirix. </p>
<p>Idefirix indeholder natrium<br />
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. dosis, dvs. det er i det 
væsentlige "natriumfrit". </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take idefirix"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take idefirix"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Idefirix vil blive ordineret af en læge med erfaring i nyretransplantationer. Det er til hospitalsbrug. 
Lægemidlet vil blive givet ved infusion i en vene i løbet af ca. 15 minutter.  </p>
<p>En sundhedsmedarbejder vil beregne den rigtige dosis for dig på grundlag af din vægt. Idefirix gives 
normalt som en enkelt dosis, men din læge kan beslutte at give dig en dosis mere før transplantationen.  </p>
<p>Information til sundhedspersoner om beregning af dosis, klargøring og infusion af Idefirix findes sidst 
i denne seddel. </p>
<p>Hvis du har fået for meget Idefirix 
Under og efter infusionen vil du blive fulgt nøje. Sundhedspersonale vil tjekke for eventuelle 
bivirkninger. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Kontakt lægen omgående, hvis du bemærker noget af følgende:</p>
<ul>
<li>Tegn på infektion såsom feber, kulderysten, hoste, svaghed eller generelt ubehag (meget 
almindelige — kan forekomme hos flere end 1 ud af 10 personer). </li>
<li>Tegn på infusionsreaktioner såsom kraftigt udslæt, åndenød, varmefornemmelse, rødmen 
(almindelige — kan forekomme hos op til 1 ud af 10 personer).  </li>
<li>Muskelsmerter eller udmattelse (symptomer på myalgi) (almindelige — kan forekomme hos op 
til 1 ud af 10 personer). </li>
</ul>
<p>Andre bivirkninger: </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>Infektioner: lungeinfektion (lungebetændelse), blodinfektioner (sepsis), maveinfektion, øvre 
luftvejsinfektion, adenovirusinfektion, parvovirusinfektion, urinvejsinfektion, influenza, 
sårinfektion, sårinfektion efter operation, infektion ved kateterstedet </li>
<li>Transplantatafstødning (IgG-antistoffer vil forsøge at afstøde din donornyre, og du kan føle 
generelt ubehag) </li>
<li>Højt eller lavt blodtryk (svimmelhed, kan være symptom på lavt blodtryk, og hovedpine kan 
være symptom på højt blodtryk)  </li>
<li>Nedsat antal røde blodlegemer (blodmangel) </li>
<li>Svimmelhed ved stillingsskifte, f.eks. når du rejser dig op </li>
<li>Hovedpine </li>
<li>Sprængte blodkar i øjet </li>
<li>Nedsat syn </li>
<li>Forøget puls </li>
<li>Smerter på infusionsstedet </li>
<li>Forhøjede leverenzymer (i blodprøver) </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige bivirkninger, som 
ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger 
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette 
lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store idefirix"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store idefirix"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. Idefirix opbevares på sygehusets apotek. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på etiketten på hætteglasset eller æsken efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2-8°C). Må ikke nedfryses. Opbevares i den originale pakning for at beskytte 
mod lys.  </p>
<p>Kemisk og fysisk stabilitet under brug efter rekonstitution og fortynding er påvist i 24 timer ved 2-8°C 
og i 4 timer ved 25°C i denne periode. </p>
<p>Anvend ikke dette lægemiddel, hvis du ser partikler eller misfarvning efter rekonstitution. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet eller toilettet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Idefirix indeholder<br />
- Aktivt stof: imlifidase. Hvert hætteglas indeholder 11 mg imlifidase. Efter rekonstitution 
indeholder 1 ml koncentrat 10 mg imlifidase.<br />
- Øvrige indholdsstoffer: mannitol, polysorbat 80, trometamol, dinatriumedetatdihydrat og 
saltsyre (til justering af pH). Se pkt. 2 "Idefirix indeholder natrium". </p>
<p>Udseende og pakningsstørrelser 
- Idefirix leveres som et hætteglas (glas) indeholdende et pulver til koncentrat til infusionsvæske, 
opløsning (pulver til koncentrat). Pulveret er hvidt, frysetørret og kompakt. 
- Pakningen indeholder 1 eller 2 hætteglas. </p>
<p>Indehaver af markedsføringstilladelse<br />
Hansa Biopharma AB<br />
P.O. Boks 220 07 Lund<br />
Sverige </p>
<p>Fremstiller 
Biotechnologines farmacijos centras Biotechpharma UAB 
Mokslininku street 4 
LT-08412 Vilnius 
Litauen </p>
<p>Propharma Group The Netherlands B.V. 
Schipholweg 2316 ZL, Leiden 
Nederlandene (Holland) </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Dette lægemiddel er godkendt under "betingede omstændigheder". Det betyder, at der forventes 
yderligere dokumentation for lægemidlet.<br />
Det Europæiske Lægemiddelagentur vil mindst en gang om året vurdere nye oplysninger om 
lægemidlet, og denne indlægsseddel vil om nødvendigt blive ajourført. </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: 
http://www.ema.europa.eu </p>
<hr />
<p>Nedenstående oplysninger er kun til sundhedspersoner: </p>
<p>Rekonstitution af pulver 
Indfør 1,2 ml sterilt vand til injektionsvæsker i hætteglasset med Idefirix. Ret vandstrålen mod glassets 
væg og ikke ned i pulveret. </p>
<p>Hvirvl opløsningen let rundt i hætteglasset i mindst 30 sekunder, så pulveret opløses fuldstændigt. 
Ryst ikke hætteglasset. Ellers er der risiko for skumdannelse. Hætteglasset vil nu indeholde imlifidase 
10 mg/ml, og op til 1,1 ml opløsning kan suges ud. </p>
<p>Den rekonstituerede opløsning bør være klar og farveløs. Hvis opløsningen indeholder partikler eller 
er misfarvet, må den ikke anvendes. Det anbefales straks at overføre den rekonstituerede opløsning fra 
glasset til infusionsposen. </p>
<p>Klargøring af infusionsvæsken, opløsning<br />
Tilføj langsomt den korrekte mængde rekonstitueret imlifidase-opløsning til en infusionspose 
indeholdende 50 ml natriumchlorid 9 mg/ml (0,9 %) infusionsvæske, opløsning. Vend infusionsposen 
op og ned flere gange, så opløsningen blandes grundigt. Infusionsposen bør beskyttes mod lys.  </p>
<p>Infusionsvæsken, opløsning inspiceres visuelt for partikler og misfarvning før anvendelse. Kassér 
opløsningen, hvis der observeres partikler eller misfarvning.  </p>
<p>Administration<br />
Hele infusionen, der skal være helt fortyndet, bør administreres over et tidsrum på 15 minutter og skal 
administreres med et infusionssæt og et sterilt, inline, pyrogenfrit filter med lav proteinbinding 
(porestørrelse 0,2 μm). Efter administration anbefales det, at den intravenøse slange skylles med 
natriumchlorid 9 mg/ml (0,9 %) infusionsvæske, opløsning, for at sikre at hele dosissen administreres 
til patienten. Opbevar ikke eventuelt resterende infusionsvæske, opløsning, til genbrug. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3713afe50f1010dc6d3a525f7492a818
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for idefirix Package Leaflet for language en"
Description: "ePI document Bundle for idefirix Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3713afe50f1010dc6d3a525f7492a818"
* entry[0].resource = composition-en-3713afe50f1010dc6d3a525f7492a818

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3713afe50f1010dc6d3a525f7492a818"
* entry[=].resource = mp3713afe50f1010dc6d3a525f7492a818
                            
                    
Instance: bundlepackageleaflet-da-3713afe50f1010dc6d3a525f7492a818
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for idefirix Package Leaflet for language da"
Description: "ePI document Bundle for idefirix Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3713afe50f1010dc6d3a525f7492a818"
* entry[0].resource = composition-da-3713afe50f1010dc6d3a525f7492a818

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3713afe50f1010dc6d3a525f7492a818"
* entry[=].resource = mp3713afe50f1010dc6d3a525f7492a818
                            
                    



Instance: mp3713afe50f1010dc6d3a525f7492a818
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Idefirix 11 mg powder for concentrate for solution for infusion"
Description: "Idefirix 11 mg powder for concentrate for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1471/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Idefirix 11 mg powder for concentrate for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 3713afe50f1010dc6d3a525f7492a818ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "idefirix"

* status = #current
* mode = #working

* title = "List of all ePIs associated with idefirix"

* subject = Reference(mp1c08ca6712ac1c2e1d3907bbfff2bcf1)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#idefirix "idefirix"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3713afe50f1010dc6d3a525f7492a818) // idefirix en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3713afe50f1010dc6d3a525f7492a818) // idefirix da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3713afe50f1010dc6d3a525f7492a818
InstanceOf: List

* insert 3713afe50f1010dc6d3a525f7492a818ListRuleset
    